PCA3 in prostate cancer and tumor aggressiveness detection on 407 high-risk patients: a National Cancer Institute experience
about
Circulating long non-coding RNAs in cancer: current status and future perspectivesPCA3 and TMPRSS2-ERG gene fusions as diagnostic biomarkers for prostate cancerThe Clinical Relevance of Long Non-Coding RNAs in CancerProstate cancer biomarkers: Are we hitting the mark?Prostate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal BiomarkersLong Noncoding RNAs as Biomarkers in Cancer.Combination of curcumin and bicalutamide enhanced the growth inhibition of androgen-independent prostate cancer cells through SAPK/JNK and MEK/ERK1/2-mediated targeting NF-κB/p65 and MUC1-C.MicroRNA-195 suppresses tumor cell proliferation and metastasis by directly targeting BCOX1 in prostate carcinoma.Biomarkers for prostate cancer: present challenges and future opportunities.Epigenomic Regulation of Androgen Receptor Signaling: Potential Role in Prostate Cancer Therapy.Epigenetic basis of cancer health disparities: Looking beyond genetic differences.'Lnc'-ing Wnt in female reproductive cancers: therapeutic potential of long non-coding RNAs in Wnt signalling.Use of two gene panels for prostate cancer diagnosis and patient risk stratification.Characterization of prostate cancer cell progression in zebrafish xenograft model.Emerging biomarkers in the diagnosis of prostate cancer.Clinical Significance of Peripheral Blood PCA3 Gene Expression in Early Diagnosis of Prostate Cancer.Role of exosomal small RNA in prostate cancer metastasisUrinary markers aiding in the detection and risk stratification of prostate cancer
P2860
Q26748862-8F2B6BBE-0720-4A2F-987E-E9CDDA61ED4AQ26752933-44080E87-9822-4B34-A896-6673ACD3D634Q26777757-0D6576C2-3C37-486F-82B7-0946A097889EQ28071654-9B5C7FFC-9F46-4EA8-BDB8-16C3FE9B9004Q28075610-A36634A6-C5E6-47F2-A223-E0C3153C0195Q33786847-2F58CF6E-8A6E-47FE-8947-46C8A3A5469BQ35658479-96856236-4DA6-4A60-8DCF-AB3B808C8052Q36025254-A4292B01-E44E-41D3-89C2-769D5ED03F8BQ37474443-AB12360B-DB2E-488A-A3FD-C69CD25D1E7EQ37629548-B0AF45E2-6E6F-49FD-A6F9-00B493C42A68Q39096966-B331DED0-9891-4A1B-B011-A023BFDC5C72Q39453727-6300D733-D789-41DE-A2B9-0B404978C6FDQ40945727-7025CBE0-00A3-4EBC-A63E-6CF8D1AC3A4AQ47426582-FAAF84BD-842B-4736-8B90-8B6DA1A84319Q54964875-23BDB52C-973B-4A18-8767-803C6883A28EQ55241328-791C175F-1E0D-45FD-96DE-8B17BB293CA4Q57489975-B06B8F5E-E478-430B-B4F0-6A32105E523EQ58562073-85DB20B5-DF77-4681-B310-5D484FBF6BC3
P2860
PCA3 in prostate cancer and tumor aggressiveness detection on 407 high-risk patients: a National Cancer Institute experience
description
2015 nî lūn-bûn
@nan
2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
PCA3 in prostate cancer and tu ...... al Cancer Institute experience
@ast
PCA3 in prostate cancer and tu ...... al Cancer Institute experience
@en
type
label
PCA3 in prostate cancer and tu ...... al Cancer Institute experience
@ast
PCA3 in prostate cancer and tu ...... al Cancer Institute experience
@en
prefLabel
PCA3 in prostate cancer and tu ...... al Cancer Institute experience
@ast
PCA3 in prostate cancer and tu ...... al Cancer Institute experience
@en
P2093
P2860
P50
P1476
PCA3 in prostate cancer and tu ...... al Cancer Institute experience
@en
P2093
Anna Antenucci
Chiara Mandoj
Giovanni Cigliana
Giulia Orlandi
Giuseppe Cusumano
Manuela Costantini
Paolo Ascenzi
Roberta Merola
Salvatore Guaglianone
Serena Masi
P2860
P2888
P356
10.1186/S13046-015-0127-8
P577
2015-02-06T00:00:00Z
P5875
P6179
1003652370